What do systematic reviews say?

Anti‐EGFR antibody plus chemotherapy vs chemotherapy alone

The review found no eligible studies for this question.

• Epidermal growth factor receptor blockers for the treatment of ovarian cancer 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Chemotherapy vs gemcitabine

Various types of chemotherapy probably leads to higher overall survival ‐ 5FU compared with gemcitabine (moderate certainty).

• Chemotherapy and radiotherapy for advanced pancreatic cancer 2018 · Cochrane Headline outcomes only
  HR 1.69 [1.26, 2.27]
  1 study · 126 participants
  Moderate

Chemotherapy vs gemcitabine

Various types of chemotherapy probably leads to lower overall survival ‐ FOLFIRINOX compared with gemcitabine (moderate certainty).

• Chemotherapy and radiotherapy for advanced pancreatic cancer 2018 · Cochrane Headline outcomes only
  HR 0.51 [0.43, 0.6]
  2 studies · 652 participants
  Moderate

Chemotherapy vs gemcitabine

Various types of chemotherapy leads to lower overall survival ‐ Fixed dose rate gemcitabine compared with gemcitabine (high certainty).

• Chemotherapy and radiotherapy for advanced pancreatic cancer 2018 · Cochrane Headline outcomes only
  HR 0.79 [0.66, 0.94]
  2 studies · 644 participants
  High

Chemotherapy vs gemcitabine

Various types of chemotherapy showed no clear difference in overall survival ‐ CO‐101 compared with gemcitabine (moderate certainty).

• Chemotherapy and radiotherapy for advanced pancreatic cancer 2018 · Cochrane Headline outcomes only
  HR 1.07 [0.86, 1.34]
  1 study · 367 participants
  Moderate

Chemotherapy vs gemcitabine

Various types of chemotherapy showed no clear difference in overall survival ‐ ZD9331 compared with gemcitabine (moderate certainty).

• Chemotherapy and radiotherapy for advanced pancreatic cancer 2018 · Cochrane Headline outcomes only
  HR 0.86 [0.42, 1.76]
  1 study · 55 participants
  Moderate

Chemotherapy vs gemcitabine

Various types of chemotherapy showed no clear difference in overall survival ‐ Exatecan compared with gemcitabine (moderate certainty).

• Chemotherapy and radiotherapy for advanced pancreatic cancer 2018 · Cochrane Headline outcomes only
  HR 1.27 [0.96, 1.68]
  1 study · 339 participants
  Moderate

Chemotherapy (any regimen; added to, or compared with, locoregional treatment) vs Locoregional treatment and/or an alternative chemotherapy regimen

The review found no eligible studies for this question.

• Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy 2021 · Cochrane All outcomes
  Quality of life was a planned (protocol) outcome but no included trial provided usable quality-of-life data; the protocol was modified to report only survival/response outcomes.
  0 studies
  No studies found

High‐dose chemotherapy followed by autologous haematopoietic cell transplantation vs conventional chemotherapy plus whole lung irradiation

High‐dose chemotherapy followed by autologous haematopoietic cell… showed no clear difference in event‐free survival (reported as number of participants with… compared with conventional chemotherapy plus whole lung irradiation (low certainty).

• High‐dose chemotherapy followed by autologous haematopoietic cell transplantation for children, adolescents, and young… 2021 · Cochrane Headline outcomes only
  HR 0.83 [0.59, 1.17]
  1 study · 267 participants
  Low

High‐dose chemotherapy followed by autologous haematopoietic cell transplantation vs conventional chemotherapy plus whole lung irradiation

The review found no eligible studies for this question.

• High‐dose chemotherapy followed by autologous haematopoietic cell transplantation for children, adolescents, and young… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

High‐dose chemotherapy followed by autologous haematopoietic cell transplantation vs conventional chemotherapy plus whole lung irradiation

The review found no eligible studies for this question.

• High‐dose chemotherapy followed by autologous haematopoietic cell transplantation for children, adolescents, and young… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

High‐dose chemotherapy followed by autologous haematopoietic cell transplantation vs conventional chemotherapy plus whole lung irradiation

The review found no eligible studies for this question.

• High‐dose chemotherapy followed by autologous haematopoietic cell transplantation for children, adolescents, and young… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

High‐dose chemotherapy followed by autologous haematopoietic cell transplantation vs conventional chemotherapy plus whole lung irradiation

The review found no eligible studies for this question.

• High‐dose chemotherapy followed by autologous haematopoietic cell transplantation for children, adolescents, and young… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Anti‐angiogenic drugs plus chemotherapy vs chemotherapy alone

Anti‐angiogenic drugs plus chemotherapy probably leads to lower overall survival† compared with chemotherapy (moderate certainty).

• Systemic treatments for metastatic cutaneous melanoma 2018 · Cochrane Headline outcomes only
  HR 0.6 [0.45, 0.81]
  324 participants
  Moderate

Anti‐angiogenic drugs plus chemotherapy vs chemotherapy alone

Anti‐angiogenic drugs plus chemotherapy probably leads to lower progression‐free survival† compared with chemotherapy (moderate certainty).

• Systemic treatments for metastatic cutaneous melanoma 2018 · Cochrane Headline outcomes only
  HR 0.69 [0.52, 0.92]
  324 participants
  Moderate

Anti‐angiogenic drugs plus chemotherapy vs chemotherapy alone

Anti‐angiogenic drugs plus chemotherapy showed no clear difference in tumour response compared with chemotherapy (moderate certainty).

• Systemic treatments for metastatic cutaneous melanoma 2018 · Cochrane Headline outcomes only
  RR 1.71 [0.96, 3.03]
  324 participants
  Moderate

Anti‐angiogenic drugs plus chemotherapy vs chemotherapy alone

Anti‐angiogenic drugs plus chemotherapy showed no clear difference in toxicity (≥ G3) compared with chemotherapy (low certainty).

• Systemic treatments for metastatic cutaneous melanoma 2018 · Cochrane Headline outcomes only
  RR 0.68 [0.09, 5.32]
  324 participants
  Low

Summary of findings 1: PLD with chemotherapy vs alternative combination chemotherapy

Summary of findings 1: PLD with chemotherapy showed no clear difference in overall survival (OS) compared with alternative combination chemotherapy (moderate certainty).

• Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  HR 0.93 [0.83, 1.04]
  5 studies · 2006 participants
  Moderate

Summary of findings 1: PLD with chemotherapy vs alternative combination chemotherapy

Summary of findings 1: PLD with chemotherapy probably leads to lower progression‐free survival (PFS) compared with alternative combination chemotherapy (moderate certainty).

• Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  HR 0.81 [0.74, 0.89]
  5 studies · 2006 participants
  Moderate

Summary of findings 1: PLD with chemotherapy vs alternative combination chemotherapy

• Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 608 participants
  Low